[GlobeNewswire] - NEW YORK -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the pricing of an underwritten public offering ...
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment